Evaluation of the customer issue included a review of the complaint text, a search for similar complaints, device history review, labeling review, and field data review.No adverse trend was identified for the customer issue.Device history review did not identify any issues that may have caused the customer issue.Labeling was reviewed and found to be adequate.Review of field data showed the complaint lot patient median value was within established control limits and no unusual reagent performance was identified.Based on all available information and abbott diagnostics evaluation, no systemic issue was identified and no product deficiency was found.This report is being filed on an international product, list number 2k91-32 that has a similar products distributed in the us, list number 2k91-29/2k91-33.
|
The customer observed falsely elevated results while using architect ca 19-9xr reagents.The following data was provided.(b)(6) initial 56.4 u/ml, repeat 2.4, 3.2 u/ml no previous values were provided and the customer believes the lower values are correct.It was unknown if the patient had been diagnosed with pancreatic cancer.No impact to patient management were reported.
|